Licochalcone a: A promising antiparasitic drug against giardiasis.

Giardiasis, caused by Giardia duodenalis, is a prevalent and significant zoonotic disease. While nitroimidazole drugs are primarily used to treat giardiasis, the urgent need for the development and formulation of new drugs has arisen due to increasing drug resistance. Several plant derived medicine have been employed as antiparasitic drugs.

Survival Outcomes of U.S. Patients with CMML: A Two-Decade Analysis from the SEER Database.

Chronic Myelomonocytic Leukemia (CMML) is a rare and aggressive form of leukemia with characteristics of both myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDSs). This study aims to explore the clinical features, survival outcomes, and prognostic factors in CMML patients over the past 20 years using a large sample. The study data from 4124 patients diagnosed with CMML between 2000 and 2017 were sourced from the SEER database.

Pt Single Atom-Doped Triphasic VP-NiP-MoP Heterostructure: Unveiling a Breakthrough Electrocatalyst for Efficient Water Splitting.

Enhancement of an alkaline water splitting reaction in Pt-based single-atom catalysts (SACs) relies on effective metal-support interactions. A Pt single atom (Pt)-immobilized three-phased Pt@VP-NiP-MoP heterostructure on nickel foam is presented, demonstrating high catalytic performance. The existence of Pt on triphasic metal phosphides gives an outstanding performance toward overall water splitting.

Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic malignancy with limited treatment options. Currently, standard treatment strategies include clinical trials; chemotherapy regimens such as hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD); and tagraxofusp-erzs (TAG, previously SL-401) which is the first-in-class targeted therapy against CD123. TAG received Food and Drug Administration approval for frontline BPDCN treatment in December 2018 and has increasingly become an alternative to chemotherapy, offering potentially more effective and less toxic options.